ATLANTA - Reverse payment settlements between the holder of a drug patent and generic manufacturers of the drug did not constitute an unfair restraint on trade in violation of Section 5(a) of the Federal Trade Commission Act 15 U.S.C.S. §45, the 11th Circuit U.S. Court of Appeals ruled April 25 in affirming the dismissal of the Federal Trade Commission's antitrust lawsuit (Federal Trade Commission v. Watson Pharmaceuticals, Inc., et al., No. 10-12729, 11th Cir.; 2012 U.S. App. LEXIS 8377).